Boster Bio Life Science Blog

  1. Research Spotlight - June 2022

    The June issue of Research Spotlight highlights research advancements from scientists whom we have served.

    Read about new studies outlining potential treatments to promote tissue repair and regeneration. For example, one study demonstrated the significance of EE for cardiac repair.

    Scientists also investigated the promising roles of ROS-scavenging hydrogel, responsive Mn3O4 nanoplatform, and a novel 3D-printed porous bioactive ceramic scaffold for spinal cord injury, gastric cancer, and bone injury, respectively.

    Other papers uncovered the molecular mechanisms of SIRT1, Neat1, cathepsin B/NLRP3, and FASN in different diseases and cancer.

    Scroll down to learn more about these 10 research discoveries.

    Environmental Eustress Improves Postinfarction Cardiac Repair via Enhancing Cardiac Macrophage Survival

    Authors: Bai, P.Y., Chen, S.Q., Jia, D.L., Pan, L.H., Liu, C.B., Luo, J.L., Yang, Y…
    Journal: Science Advances

    Macrophages play a vital role in cardiac repair following myocardial infarction (MI). An enriched environment (EE) is involved in the regulation of macrophage-related activities and disease progression; however, whether EE affects the phenotype and function of macrophages to improve postinfarction cardiac repair remains unknown...

    Read More

    Cited Boster Product(s): Mouse BDNF ELISA Kit PicoKine® (EK0309)

    Journal Cover

    Catalpol Enhances Random-Pattern Skin Flap Survival by Activating SIRT1-Mediated Enhancement of Autophagy

    Authors: Jiang, R.H., Dong, C.J., Chen, Z.L., Cheng, S., Yang, J.X., Gao, W.Y.
    Journal: Oxidative Medicine and Cellular Longevity

    Random-pattern skin flap necrosis limits its application in the clinic. It is still a challenge for plastic surgeons. Catalpol is an effective ingredient extracted from Rehmannia glutinosa, which is reported to promote angiogenesis and protect against ischemic cerebral disease. The aim of our experiment is to assess whether catalpol...

    Read More

    Cited Boster Product(s): Anti-VE-Cadherin-5 Cdh5-Antibody Picoband™ (A02632-2)

    Read more
    Research Spotlight - June 2022
  2. Research Spotlight - April 2022

    Every month, we feature 10 research studies from scientists whom we have served. In our April edition of Research Spotlight, scientists focus on finding novel delivery systems to improve the poor delivery efficiency of therapeutic biomolecules.

    One research paper provided new insights into how renal exosomes are aroused by β-catenin, underscoring an important therapeutic strategy for CKD. Studies highlighting the promising potential of engineered EGCG-containing nanoassemblies, microalgae-based...

    Read more
    Research Spotlight - April 2022
  3. Research Spotlight - November 2021

    Our November edition of Research Spotlight highlights 10 research studies that provide deeper insights on the biological functions of several key biomarkers and their clinical translational potential.

    Two studies reveal new insights for diabetes treatment by investigating the functions of PGRMC1 and an m6A reader protein for insulin metabolism and delayed diabetic wound healing respectively.

    Scientists also perform bioinformatics and immunological analysis of several regulatory...

    Read more
    Research Spotlight - November 2021
  4. Research Spotlight - October 2021

    We're delighted to bring you our October edition of Research Spotlight, featuring 10 new publications of various fields from scientists whom Boster has served.

    This month, research papers delve into nanotechnology advancements using polydopamine nanoparticles, PLGA nanoparticles, and HA-coated collagen nanofibers for cancer treatments and regenerative medicine.

    Scientists also investigate how exercise can ameliorate tumor-associated anemia, how the SARS-CoV-2 virus crosses the...

    Read more
    Research Spotlight - October 2021
  5. Research Spotlight - September 2021

    The September edition of Research Spotlight presents 10 recent publications from scientists whom Boster has served.

    This month’s selected research papers characterize the underlying mechanisms of several cancers, HIV, and other systemic diseases. Among the studies, monoclonal antibodies and a tumor nanovaccine are explored as therapeutic treatments for different cancers.

    Scientists also demonstrate how a 3D-printed biphasic scaffold can enhance cartilage regeneration. In addition, the role of PEDF in collagen synthesis and its implications for tissue expansion in plastic surgery is investigated.

    Keep scrolling to find out more about these research studies.

    Characterizing Dedifferentiation of Thyroid Cancer by Integrated Analysis

    Authors: Luo, H., Xia, X., Kim, G.D., Liu, Y., Xue, Z., Zhang, L., Shu, Y., Yang, T...
    Journal: Science Advances

    Understanding of dedifferentiation, an indicator of poo prognosis for patients with thyroid cancer, has been hampered by imprecise and incomplete characterization of its heterogeneity and its attributes. Using single-cell RNA sequencing, we explored the landscape of thyroid cancer at single-cell resolution with 46,205 cells and...

    Read More

    Cited Boster Product(s): Anti-Vimentin Antibody Picoband™ (PB9359); Anti-E Cadherin 1/CDH1 Antibody Picoband™ (PB9561)

    Journal Cover

    Oral Immune Dysfunction is Associated with the Expansion of FOXP3+PD-1+Amphiregulin+ T Cells During HIV Infection

    Authors: Bhaskaran, N., Schneider, E., Faddoul, F., da Silva, A.P., Asaad, R...
    Journal: Nature Communications

    >Residual systemic inflammation and mucosal immune dysfunction persist in people living with HIV, despite treatment with combined anti-retroviral therapy, but the underlying immune mechanisms are poorly understood. Here we report that the altered immune landscape of the oral mucosa of HIV-positive patients on therapy involves...

    Read More

    Cited Boster Product(s): Human CD14 ELISA Kit PicoKine™ (EK0694); Human TLR2/Toll-Like Receptor 2 ELISA Kit PicoKine™ (EK0906); Human Cotinine ELISA Kit (Competitive EIA) (EK7035); Human Amphiregulin(AR) / AREG ELISA Kit PicoKine™ (EK0304); Human IL-1 Beta/IL-1F2/IL1B ELISA Kit PicoKine™ (EK0392); Human IL-6/Interleukin-6 ELISA Kit PicoKine™ (EK0410)

    Journal Cover

    Increased Plasmin-Mediated Proteolysis of L1CAM in a Mouse Model of idiopathic Normal Pressure Hydrocephalus

    Authors: Yang, D., Yang, H., Luiselli, G., Ogagan, C., Dai, H., Chiu, L...
    Journal: PNAS (Proceedings of the National Academy of Sciences of the United States of America)

    Idiopathic normal pressure hydrocephalus (iNPH) is a common neurological disorder that is characterized by enlarged cerebral ventricles, gait difficulty, incontinence, and dementia. iNPH usually develops after the sixth decade of life in previously asymptomatic individuals. We recently reported that loss-of-function deletions in CWH43...

    Read More

    Cited Boster Product(s): Anti-Plasminogen Antibody Picoband™ (A03674-1)

    Journal Cover

    Cooperating Minimalist Nanovaccine with PD-1 Blockade for Effective and Feasible Cancer Immunotherapy

    Authors: Jiang, M., Zhao, L., Cui, X., Wu, X., Zhang, Y., Guan, X., Ma, J...
    Journal: Journal of Advanced Research

    Introduction: Tumor vaccine has been a research boom for cancer immunotherapy, while its therapeutic outcome is severely depressed by the vulnerable in vivo delivery efficiency. Moreover, tumor immune escape is also another intractable issue, which has badly whittled down the therapeutic efficiency. Objectives: Our study aims to solve...

    Read More

    Cited Boster Product(s): FITC Conjugated Avidin (BA1125)

    Journal Cover

    Blockade of CHRNB2 Signaling with a Therapeutic Monoclonal Antibody Attenuates the Aggressiveness of Gastric Cancer Cells

    Authors: Kanda, M., Shimizu, D., Nakamura, S., Sawaki, K., Umeda, S...
    Journal: Oncogene

    Here, we evaluated the therapeutic potential of antibodies (Abs) targeting cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To investigate

    Read more
    Research Spotlight - September 2021
  6. Research Spotlight - June 2021

    Our June edition of Research Spotlight presents 10 recent research papers from scientists whom Boster has served.

    In the selected studies, you will learn how the research community is developing more efficient ways for drug delivery, utilizing biomaterials in therapeutic treatments, exploring various pathological reactions, and many more.

    Among the papers, scientists investigate how the apoptotic process can be used to load drugs for brain-targeted delivery with much higher efficiency...

    Read more
    Research Spotlight - June 2021
  7. Research Spotlight - April 2021

    Science is always evolving and advancing throughout the ongoing process of knowledge discovery. Every month, we select 10 recent publications from scientists whom Boster has served.

    Our April edition of Research Spotlight presents the latest information about various tumor-regulating genes/proteins, including BRCA1, HMGB1, EGFR, VEGFR2, PERK, and lncRNA LOC102724169. Several promising strategies to modulate immunoinflammatory microenvironments for bone regeneration and cancer are also...

    Read more
    Research Spotlight - April 2021
  8. Research Spotlight - January 2021

    Our January edition of Research Spotlight presents an array of 10 interesting developments in the biomedical world. Valuable information about proliferation of cancer cells, immunity, inflammatory bowel diseases, and the body’s responses to oxidative stress and various nutrients are discussed.

    In addition, scientists investigate how SLC19A1 as the major transporter of CDNs into cells could serve as a new potential immunotherapeutic treatment of cancer and some inflammatory diseases...

    Read more
    Research Spotlight - January 2021
  9. Research Spotlight - December 2020

    The December edition of Research Spotlight highlights 10 recent research discoveries from scientists whom Boster has served.

    In these studies, the effects of several key proteins and their signaling pathways were explored in correlation to the progression and activation of cancer cells, diabetic nephropathy, inflammation, and brain injury.

    The role of polysulfides as potential tumor suppressors and regulators might represent an alternative therapeutic candidate for the management of diabetic nephropathy. Additionally, several promising potential therapeutic strategies for enhanced immunotherapy, such as enhanced drug delivery systems, ultrasound-guided platelet-rich plasma injection, and the role of mechanical cues in vascular biology were also investigated.

    Scroll down to find more information about these new scientific discoveries.

    Polysulfide-Mediated Sulfhydration of SIRT1 Prevents Diabetic Nephropathy by Suppressing Phosphorylation and Acetylation of p65 NF-κB and STAT3

    Authors: Sun, H.J., Xiong, S.P., Cao, X., Cao, L., Zhu, M.Y., Wu, Z.Y., & Bian, J.S.
    Journal: Redox Biology

    Diabetic kidney disease is known as a major cause of chronic kidney disease and end stage renal disease. Polysulfides, a class of chemical agents with a chain of sulfur atoms, are found to confer renal protective effects in acute kidney injury. However, whether a polysulfide donor, sodium tetrasulfide (Na2S4), confers protective...

    Read More

    Cited Boster Product(s): Mouse TNF Alpha ELISA Kit PicoKine™ (EK0527); Mouse IL-1 Beta ELISA Kit PicoKine™ (EK0394); Mouse VCAM-1 ELISA Kit PicoKine™ (EK0538)

    Journal Cover

    Development of Thermosensitive Resiquimod-Loaded Liposomes for Enhanced Cancer Immunotherapy

    Authors: Zhang, H., Tang, W.L., Kheirolomoom, A., Fite, B.Z., Wu, B., Lau, K...
    Journal: Journal of Controlled Release

    Resiquimod (R848) is a toll-like receptor 7 and 8 (TLR7/8) agonist with potent antitumor and immunostimulatory activity. Howeve

    Read more
    Research Spotlight - December 2020
  10. Research Spotlight - November 2020

    In our November edition of Research Spotlight, we feature 10 recently published research papers from scientists whom Boster has served.

    This month’s selected research publications investigate how several cells and mediators regulate the development of fibrotic diseases, cancer, inflammatory responses, diabetes, allergy, endometriosis, and anxiety.

    Among the studies, scientists propose the underlying mechanisms of how endothelin receptor antagonists may serve as a therapeutic strategy for fibrotic diseases. The role of PRMT5 in laryngeal tumor carcinogenesis is also explored.

    Discover more details about these new scientific discoveries below.

    Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies

    Authors: Hughes, T.K., Wadsworth, M.H., Gierahn, T.M., Do, T., Weiss, D...
    Journal: Immunity

    High-throughput single-cell RNA-sequencing (scRNA-seq) methodologies enable characterization of complex biological samples by increasing the number of cells that can be profiled contemporaneously. Nevertheless, t

    Read more
    Research Spotlight - November 2020